Gabriela Rosu M.D.
Senior Director, Global Medical Affairs
Gabriela Rosu, M.D., is the Senior Director, Global Medical Affairs at Veristat. In her role, Dr. Rosu is responsible for the leadership and strategic direction of the Global Medical Affairs department. Among her attributions are key client oversight and strategic project input, direct management of the medical affairs team, consulting activities, and medical oversight of ongoing clinical studies.
Dr. Rosu brings over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval and commercialization of groundbreaking therapies. Dr. Rosu’s profound insight into the nuances of oncology therapy development is invaluable to clients, particularly when optimizing treatment strategies and managing compound toxicity.
Prior to joining Veristat in 2024, Dr. Rosu held senior medical affairs positions at leading global CROs where she oversaw medical monitoring for various oncology trials, advised on protocol development, risk mitigation strategies, and strategic development with a focus on patient safety and patient outcomes. Before transitioning to the CRO industry, Dr. Rosu held significant roles such as Chief Medical Officer at IMV Inc. and Global Medical Advisor at Novo Nordisk Healthcare, where she led clinical developments in oncology and coagulation disorders, among other responsibilities.
Dr. Rosu earned her Doctor of Medicine degree in Romania and has maintained active participation in prestigious organizations such as the European Society for Medical Oncology (ESMO) and the American Society for Clinical Oncology (ASCO), for which she has made significant and impactful contributions through numerous abstracts.
Dr. Rosu brings over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval and commercialization of groundbreaking therapies. Dr. Rosu’s profound insight into the nuances of oncology therapy development is invaluable to clients, particularly when optimizing treatment strategies and managing compound toxicity.
Prior to joining Veristat in 2024, Dr. Rosu held senior medical affairs positions at leading global CROs where she oversaw medical monitoring for various oncology trials, advised on protocol development, risk mitigation strategies, and strategic development with a focus on patient safety and patient outcomes. Before transitioning to the CRO industry, Dr. Rosu held significant roles such as Chief Medical Officer at IMV Inc. and Global Medical Advisor at Novo Nordisk Healthcare, where she led clinical developments in oncology and coagulation disorders, among other responsibilities.
Dr. Rosu earned her Doctor of Medicine degree in Romania and has maintained active participation in prestigious organizations such as the European Society for Medical Oncology (ESMO) and the American Society for Clinical Oncology (ASCO), for which she has made significant and impactful contributions through numerous abstracts.